# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

C. Measurand: Herpes simplex virus (HSV)

D. Type of Test: Cell culture confirmation, by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs).

E. Applicant: Diagnostic Hybrids, Inc.

# F. Proprietary and Established Names:

Proprietary Name: ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Herpes Simplex Virus Identification Kit Common Name: DFA (Direct Fluorescent Antibody) test kit for the detection of HSV in cell cultures inoculated with patient specimens.

# G. Regulatory Information:

1. Regulation section: 866.3305 Herpes simplex virus serological reagents

2. Classification: Class II

3. Product code: GQN [Antigens, CF (including CF control), herpesvirus hominis, 1, 2]

4. Panel: Microbiology (83)

# H. Intended Use:

1. Intended use(s):

Diagnostic Hybrids, Inc ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Herpes Simplex Virus Identification Kit is intended for use in the qualitative detection of human herpes simplex virus (HSV) in cell cultures by immunofluorescence using fluoresceinated monoclonal antibodies (MAbs). Negative results do not preclude an infection and should not be used as the sole basis for diagnosis, treatment or other management decisions.

Performance using direct specimen testing has not been evaluated.

2. Indication(s) for use: Same as Intended Use.

3. Special conditions for use statement(s): For prescription use only.

4. Special instrument requirements: This device requires the use of a fluorescence microscope to read device stained cultures. One should use with the correct filter combination for FITC (excitation peak $\cdot = 4 9 0 \mathrm { n m }$ , emission peak $= 5 2 0 \mathrm { n m }$ ).

# I. Device Description:

Diagnostic Hybrids ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Herpes Simplex Virus Identification Kit includes a DFA Reagent that contains a blend of four fluorescein-labeled murine monoclonal antibodies directed against a blend of 4 murine MAbs directed against two antigens of HSV-1 and two antigens of HSV-2. The kit includes the following components:

1. HSV DFA Reagent – A blend of fluorescein labeled murine monoclonal antibodies directed against 4 murine MAbs directed against two antigens of HSV-1 and two antigens of HSV-2 produced from HSV-infected cell culture. The buffered, stabilized, aqueous solution contains Evan’s Blue as a counter-stain and $0 . 1 \%$ sodium azide as preservative.

2. HSV Antigen Control Slides - Individually packaged control slides containing wells with cell culture derived positive and negative control cells. Each HSV positive well is identified. The negative wells contain uninfected cells. Each slide is intended to be stained only one time.

3. PBS Concentrate - A 40X concentrate consisting of $4 \%$ sodium azide in phosphate buffered saline (after dilution to 1X in water, the concentration of sodium azide in the solution is $0 . 1 \%$ ).

4. Mounting Fluid - an aqueous, buffered, stabilized solution of glycerol and $0 . 1 \%$ sodium azide.

# J. Substantial Equivalence Information:

1. Predicate device name(s): Bartels® Herpes Simplex Virus Fluorescent Monoclonal Antibody Test.

2. Predicate K number(s): K902662

3. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For the qualitative detection ofherpes simplex virus in cellcultures by immunofluorescenceusing fluoresceinated monoclonalantibodies. Negative results donot preclude an infection andshould not be used as the solebasis for diagnosis, treatment orother management decisions.Performance using directspecimen testing has not beenevaluated.</td><td colspan="1" rowspan="1">Bartels® Herpes Simplex VirusFluorescent Monoclonal AntibodyTest is intended for use in thequalitative identification of HSVculture isolates.</td></tr><tr><td colspan="1" rowspan="1">Basic principle</td><td colspan="1" rowspan="1">Direct Fluorescent Antibody(DFA) test - Immunofluorescenceusing fluoresceinated MAbs.</td><td colspan="1" rowspan="1">DFA (Direct FluorescentAntibody) test -Immunofluorescence using</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">fluoresceinated MAbs.</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">Blend of 4 murine MAbs directedagainst two antigens of HSV-1and two antigens of HSV-2.</td><td colspan="1" rowspan="1">Mouse MAbs specific to HSV-1and HSV-2 antigens.</td></tr><tr><td colspan="1" rowspan="1">Instrumentation(required butnot provided)</td><td colspan="1" rowspan="1">Fluorescence microscope withthe correct filter combination forFITC (excitation peak = 490 nm,emission peak = 520nm).</td><td colspan="1" rowspan="1">Fluorescence microscope with thecorrect filter combination for FITC(excitation peak = 490 nm,emission peak = 520nm).</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Specimens of vesicular fluid;swabbed areas or lesionscontained in transport medium</td><td colspan="1" rowspan="1">Specimens of vesicular fluid;swabbed areas or lesions containedin transport medium.</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Procedural</td><td rowspan=1 colspan=1>Immunofluorescence testingfollowing amplification in cellculture only.</td><td rowspan=1 colspan=1>Results are considered presumptivefor identification of HSV from directpatient specimens usingfluoresceinated monoclonalantibodies.</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable): N/A

# L. Test Principle:

The test kit uses a blend of four viral antigen-specific murine MAbs which are directly labeled with fluorescein for rapid identification of HSV in cell culture.

The cells to be tested, derived from cell culture, are fixed in acetone. The HSV DFA Reagent is added to the cells to determine the presence of viral antigens. After incubating at $3 5 \mathrm { { ^ \circ C } }$ to $3 7 \mathrm { { ^ \circ C } }$ , the stained cells are rinsed with the diluted PBS Concentrate, a drop of the supplied Mounting Fluid is added and a coverslip is placed on the prepared cells. The cells are examined using a fluorescence microscope. HSV-infected cells will be stained with viral specific apple-green fluorescence when stained with the HSV DFA Reagent while uninfected cells will contain no fluorescence but will be stained dull red by the Evan’s Blue counter-stain.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Not applicable.   
b. Linearity/assay reportable range: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): Not applicable

d. Detection limit: This testing is not considered necessary during premarket notification process because performance testing has been done using a comparative device in amplified cell culture (cell culture is not part of the review process for this device).

# e. Analytical specificity:

The HSV ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Reagent was tested for cross-reactivity against a wide variety of cells and microorganisms. No cross-reactivity was observed for 59 viral strains (cultured and processed for staining) or for 17 host culture cell types.

1. Depending on the particular virus used, a concentration of 150 to 715 $\mathrm { T C I D } _ { 5 0 }$ of selected virus was inoculated into shell vial or multiwell plate cultures and incubated for 24 to 48 hours to yield what was considered a $1 +$ to $^ { 3 + }$ cytopathic effect. Only confluent monolayer cell cultures were stained. The culture was processed and stained with the DFA reagent at a 1.5X working dilution concentration and processed according to the procedure detailed in each respective product insert. Stained cells were examined at $2 0 0 \mathrm { { x } }$ magnification.

ii Twenty-seven (27) bacterial cultures, one yeast and one protozoan culture were stained and examined for cross-reactivity, including Staphylococcus aureus, a protein-A-producing bacterium. Staining of S. aureus appeared as small points of fluorescence while all other cultures were negative.

1. Bacteria and yeast were cultured, processed as suspensions, and then spotted onto microscopic slides (having CFUs ranging from $6 . 4 \mathrm { x } 1 0 ^ { 4 }$ to $\dot { 2 } . 9 3 \mathrm { x } 1 0 ^ { 7 } / \mathrm { w e l l } .$ , depending on the bacterium), and stained with the DFA reagent at a 1.5X working dilution concentration and processed according to each respective product insert. Stained slides were examined at 400X magnification. Some of the microorganisms listed below were procured from an external source as prepared microscope slides (marketed for quality control use).

2. Such binding can be distinguished from viral antigen binding on the basis of morphology, i.e., S. aureus-bound fluorescence appears as small $( \sim 1$ micron diameter), bright punctuate dots.

iii Various conditions for cross-reactivity testing were achieved by using a relatively high concentration of the HSV ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Reagent (1.5X) and testing relatively high titers of microorganisms commensurate with infectious states in human. The HSV ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA Reagent was prepared at 1.5X the concentration that is provided in the kit.

No cross reactivity was observed for the viruses, cell lines, bacteria listed in the next 3 Tables:

<table><tr><td rowspan=1 colspan=7>Virus Strains Tested for Cross Reactivity with D³ HSV DFA Reagent</td></tr><tr><td rowspan=1 colspan=1>Organism</td><td rowspan=1 colspan=1>Strain orType</td><td rowspan=1 colspan=2>Inoculum(TCID50)</td><td rowspan=1 colspan=1>Organism</td><td rowspan=1 colspan=1>Strain or Type</td><td rowspan=1 colspan=1>Inoculum(TCID50)</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 1</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Hong Kong</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 3</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Maryland</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 5</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Mass</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 6</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Taiwan</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 7</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>GL</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 8</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>JH-001 isolate</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 10</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Influenza B</td><td rowspan=1 colspan=1>Russia</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 13</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>RSV</td><td rowspan=1 colspan=1>Long</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 14</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>RSV</td><td rowspan=1 colspan=1>Wash</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 18</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>RSV</td><td rowspan=1 colspan=1>9320</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 31</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 1</td><td rowspan=1 colspan=1>C-35</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 40</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 2</td><td rowspan=1 colspan=1>Greer</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Adenovirus</td><td rowspan=1 colspan=1>Type 41</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 3</td><td rowspan=1 colspan=1>C 243</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Aichi</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 4a</td><td rowspan=1 colspan=1>M-25</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Mal</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Parainfluenza 4b</td><td rowspan=1 colspan=1>CH19503</td><td rowspan=1 colspan=1>715</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Hong Kong</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>Towne</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Denver</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>Davis</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Port Chalmers</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>CMV</td><td rowspan=1 colspan=1>AD169</td><td rowspan=1 colspan=1>700</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>Victoria</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>VZV</td><td rowspan=1 colspan=1>Webster</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>New Jersey</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>VZV</td><td rowspan=1 colspan=1>Allen</td><td rowspan=1 colspan=1>500</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>PR</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Epstein-Barr</td><td rowspan=3 colspan=2>Commercially available slides stained.1</td></tr><tr><td rowspan=1 colspan=1>Influenza A</td><td rowspan=1 colspan=1>WS</td><td rowspan=1 colspan=2>715</td><td rowspan=1 colspan=1>Rubeola</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=1>Mumps</td></tr><tr><td rowspan=1 colspan=1>Echovirus</td><td rowspan=1 colspan=1>Types 4, 6, 9,11, 30, 34</td><td rowspan=1 colspan=2>Commerciallyavailable slidesstained.</td><td rowspan=1 colspan=1>HPV</td><td rowspan=1 colspan=1>Types 6, 11</td><td rowspan=1 colspan=1>Commerciallyavailable slidesstained.I</td></tr><tr><td rowspan=1 colspan=1>Coxsackievirus</td><td rowspan=1 colspan=1>Types B1, B2,B3, B4, B5, B6</td><td rowspan=1 colspan=2>Commerciallyavailable slidesstained.</td><td rowspan=1 colspan=3></td></tr><tr><td rowspan=1 colspan=7>Cell Lines Tested for Cross Reactivity with D3 HSV DFA Reagent</td></tr><tr><td rowspan=1 colspan=3>A-549</td><td rowspan=1 colspan=4>NCI-H292</td></tr><tr><td rowspan=1 colspan=3>BGMK</td><td rowspan=1 colspan=4>pCMK</td></tr><tr><td rowspan=1 colspan=3>HEp-2</td><td rowspan=1 colspan=4>pRhMK</td></tr><tr><td rowspan=1 colspan=3>LLC-MK2</td><td rowspan=1 colspan=4>RhMK II</td></tr><tr><td rowspan=1 colspan=3>MDCK</td><td rowspan=1 colspan=4>pRK</td></tr><tr><td rowspan=1 colspan=3>MRC-5</td><td rowspan=1 colspan=4>RD</td></tr><tr><td rowspan=1 colspan=3>MRHF</td><td rowspan=1 colspan=4>R-Mix</td></tr><tr><td rowspan=1 colspan=3>Mv1Lu</td><td rowspan=1 colspan=4>Vero &amp; WI-38</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Microorganisms Tested for Cross Reactivity with D3 HSV DFA Reagent</td></tr><tr><td rowspan=1 colspan=1>BACTERIA</td><td rowspan=1 colspan=2>CFU TESTED</td></tr><tr><td rowspan=1 colspan=1>Acinetobacter calcoaceticus</td><td rowspan=1 colspan=2>9.7 x 105</td></tr><tr><td rowspan=1 colspan=1>Bordetella bronchiseptica</td><td rowspan=1 colspan=2>1.7 x 105</td></tr><tr><td rowspan=1 colspan=1>Bordetella pertussis</td><td rowspan=1 colspan=2>4.6 x 106</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium diphtheriae</td><td rowspan=1 colspan=2>2.5 x 106</td></tr><tr><td rowspan=1 colspan=1>Escherichia coli</td><td rowspan=1 colspan=2>2.6 x 105</td></tr><tr><td rowspan=1 colspan=1>Gardnerella vaginalis</td><td rowspan=1 colspan=1>5.0 x 10^$</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Haemophilis influenzae type A</td><td rowspan=1 colspan=1>9.3 x 105</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae</td><td rowspan=1 colspan=1>6.4 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Legionella pneumophila</td><td rowspan=1 colspan=1>6.5 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Moraxella cartarrhalis</td><td rowspan=1 colspan=1>6.4 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Neisseria gonorrhoeae</td><td rowspan=1 colspan=1>1.3 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Proteus mirabilis</td><td rowspan=1 colspan=1>2.1 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>1.0 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Salmonella enteriditis</td><td rowspan=1 colspan=1>2.5 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Salmonella typhimurium</td><td rowspan=1 colspan=1>1.7 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1>1.0 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Streptococcus agalactiae</td><td rowspan=1 colspan=1>9.6 x 106</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>8.0 x 105</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Streptococcus pyogenes</td><td rowspan=1 colspan=1>2.9 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Acholeplasma laidlawi</td><td rowspan=1 colspan=1>~6 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Mycoplasma hominis</td><td rowspan=1 colspan=1>~6 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Mycoplasma orale</td><td rowspan=1 colspan=1>~6 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=1>~6 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Mycoplasma salivarium</td><td rowspan=1 colspan=1>~6 x 107</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Ureaplasma uralyticum</td><td rowspan=1 colspan=1>~6 x 104</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Chlamydophila pneumoniae</td><td rowspan=1 colspan=2>Commercially available slides stained. 1</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis</td><td rowspan=1 colspan=2>Commercially available slides stained. 1</td></tr><tr><td rowspan=1 colspan=1>YEAST</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Candida glabrata</td><td rowspan=1 colspan=2>8.7 x 106</td></tr><tr><td rowspan=1 colspan=1>PROTOZOAN</td><td rowspan=1 colspan=2></td></tr><tr><td rowspan=1 colspan=1>Trichomonas vaginalis</td><td rowspan=1 colspan=2>[Commercially available slides stained.]</td></tr></table>

f. Assay cut-off: Not applicable

2. Comparison studies:

# a. Method comparison with predicate device:

Comparative studies included five hundred and thirty (530) prospectively collected specimens submitted for HSV culture. Each specimen was evaluated by the ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV Identification Kit and compared to a currently marketed HSV identification kit. A combination of fresh (250) and frozen (280) specimens were tested. Although fresh and frozen specimen results are normally presented separately, combining results for performance characteristics of this device is

considered acceptable because direct patient specimen testing was not performed at all sites. Only cell culture confirmation with this device was performed. Evaluations were conducted at three external laboratory sites located in the midwest United States and one in-house virology laboratory. Three specimens from site 4 were not evaluated due to bacterial contamination of the monolayers, leaving 527 for analysis. Each of the study sites tested different legally marketed HSV kits as comparison devices.

Percent Agreement between the ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV and Comparison Devices was calculated and tabulated for all the tested specimens, and is presented in the Table below. Data are represented as positive and negative percent agreement between ${ \boldsymbol { \mathrm { D } } } ^ { 3 }$ DFA HSV Kit and a comparative device (statistically calculating the 95 percent confidence interval for each positive and negative percent agreement by the exact method).

# Results from Testing All Specimens:

<table><tr><td colspan="4">D3 DFA HSV Kit and a Legally Marketed Device (Comparison Device)</td></tr><tr><td colspan="4">Comparison Device</td></tr><tr><td rowspan="3">D3 DFA HSV</td><td></td><td>+</td><td>&#x27;</td></tr><tr><td>+</td><td>200</td><td>1</td></tr><tr><td></td><td>1</td><td>325</td></tr></table>

<table><tr><td rowspan="3">Positive Percent Agreement (PPA) =[ Negative Percent Agreement (NPA) =</td><td></td><td>95% CI</td></tr><tr><td>99.5%</td><td>97.3 to 100%</td></tr><tr><td>99.7%</td><td>98.3% - 100%</td></tr></table>

# Results from Individual Study Sites:

<table><tr><td rowspan=7 colspan=4>Study Site 1 Results (Tube cultures):Comparison Device+             -+           63            0D^3DFA HSV0            4495% CIPPA=    100%          94.2% - 100%NPA=    100%          91.9% - 100%</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>94.2% - 100%</td></tr><tr><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>91.9% - 100%</td></tr><tr><td rowspan=3 colspan=4>Study Site 2 Results (Shell vial culture):Comparison Device+             </td></tr><tr><td rowspan=7 colspan=1>D^{DFA HSVPPA=NPA=</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>79</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>92.8% - 100%</td></tr><tr><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>95.3% - 100%</td></tr></table>

# Study Site 3 Results (Tube culture):

Comparison Device   

<table><tr><td></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>97.9%</td><td rowspan=1 colspan=2>88.9 to 99.9%</td></tr><tr><td rowspan=1 colspan=1>99.1%</td><td rowspan=1 colspan=2>94.7% -100.0%</td></tr></table>

# Study Site 4 Results (Multi-well plate culture):

Comparison Device   

<table><tr><td></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>95% CI</td></tr><tr><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>91.1% - 100%</td></tr><tr><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=2>96.3% - 100%</td></tr></table>

b. Matrix comparison: Not applicable.

3. Clinical studies: Testing was performed with clinically collected specimens submitted to the four different laboratories for HSV testing. Results were compared with a legally marketed HSV device(s).

a. Clinical Sensitivity: Not applicable.   
b. Clinical specificity: Not applicable.   
c. Other clinical supportive data: Not applicable.

4. Clinical cut-off: Not applicable.

5. Expected values/Reference range: Not applicable.

N. Proposed Labeling: The labeling is considered adequate and satisfies the requirements of 21 CFR Part 809.10 for safety and effectiveness and substantial equivalence to a legally marketed device.

O. Conclusion: The submitted information in this premarket notification is considered complete and supports a substantial equivalence decision.